A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
You'll have option to make 4 interest-free payments by credit card once your order is confirmed using
Fluphenazine is a First Generation Antipsychotic (FGA) used for the treatment of mental health disorders. Examples include bipolar disorder, schizophrenia, and schizoaffective disorder. It also has usage in the management of tics in people with Tourette’s syndrome.
Fluphenazine is a piperazine phenothiazine FGA that works by increasing dopamine levels in certain areas of the brain. Regulating dopamine levels can improve psychotic symptoms.
The dosage is 2.5-10 mg by mouth divided into three or four dosages. Some patients may require much higher dosages, like 40 mg daily.
The active ingredient is fluphenazine.
The most common drug-drug interactions may include:
Tell your doctor if you have a history of heart conditions before starting this drug.
Long-term usage of FGA increases the risk of extrapyramidal symptoms (EPS).
Fluphenazine has a higher risk of causing central nervous system (CNS) depression.
Ask your doctor and pharmacist for a complete list of precautions.
Common adverse reactions include
Fluphenazine Hydrochloride [package insert]. Philadelphia, PA: Lannett Company, Inc.; 2019.